Our longest, most thorough research write-ups on individual compounds. Evidence first, hype last.
A full, honest deep dive on BPC-157: what it is, how it works, what the animal and human evidence really show, the tumor question, dosing as reported, and its 2026 legal status.
A full deep dive on TB-500: why it is not the same molecule as Thymosin Beta-4, what the evidence shows, the grounded tumor concern, reported dosing, and where it stands legally.
A full deep dive on KPV: the alpha-MSH anti-inflammatory tripeptide, its gut and skin research, why human evidence is absent, reported dosing, and its 2026 legal status.
A full deep dive on GHK-Cu: the copper peptide with real topical evidence, the crucial topical-versus-injectable split, mechanisms, reported dosing, and its legal status.
A full, evidence-based deep dive on semaglutide: what it is, how GLP-1 works, what the trials actually show for diabetes and weight, the risks, and where it stands legally.
The complete picture on tirzepatide, the dual GIP and GLP-1 drug: how it works, the SURPASS and SURMOUNT trial results, side effects, and how it compares to semaglutide.
A grounded deep dive on retatrutide, the triple-agonist drug: the TRIUMPH Phase 3 weight results, the side effects, what is still unknown, and why it is not approved yet.
An honest deep dive on ipamorelin, the selective growth-hormone peptide: how it works, the thin human evidence, why it is stacked with CJC-1295, the risks, and its legal limbo.
The full deep dive on CJC-1295 with DAC: the long-acting GHRH peptide, the with-DAC versus without-DAC distinction, the one 2006 human study, the trial-death myth, and the risks.
A route-by-route deep dive on glutathione: the master antioxidant, what oral and topical use can and cannot do, why injectable and IV whitening is flagged, and the 2026 recalls.
An honest deep dive on MOTS-c, the mitochondrial peptide called exercise in a bottle: the mouse data, the missing human trials, the CB4211 story, and the July 2026 FDA vote.
A full deep dive on Semax, the Russian nootropic and stroke peptide: what it is, the BDNF research, the weak human evidence, side effects, and the 8 to 5 FDA panel vote.
The honest picture on Epitalon and telomeres: who ran the research, what the cell and mouse studies show, the real cancer question, and the July 2026 FDA vote for insomnia.
A route-by-route deep dive on NAD+: what it does in the body, what really happens to an IV dose, the thin human evidence, the infusion side effects, and compounding status.
A full deep dive on Selank, the Russian anti-anxiety peptide: the one small human trial, the GABA and enkephalin research, the risks, and why it was not in the 2026 FDA review.
An honest deep dive on DSIP, the delta sleep-inducing peptide: the 1977 rabbit research, the tiny and conflicting sleep trials, and why it was the one peptide the FDA panel rejected.
A full deep dive on tesamorelin (Egrifta), the FDA-approved GHRH analog: the belly-fat trials in HIV, what happens when you stop, blood sugar risks, and why it cannot be compounded.
The full picture on PT-141, approved as Vyleesi: how it works on desire, the modest RECONNECT trial results, nausea and blood pressure effects, and the gray-market versions.
A grounded deep dive on SS-31, the mitochondria peptide: the string of missed trials, its narrow 2025 approval for Barth syndrome, injection-site reactions, and the longevity hype.
An evidence-honest deep dive on Thymosin Alpha-1 (Zadaxin): approved abroad but not in the US, the hepatitis data, the null 2025 sepsis trial, and the 17 to 4 FDA panel vote.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.